Program
DWP712
A development code. Also written as “DWP712 inj.”.
Its studies are led by Daewoong Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewoong Pharmaceutical | 21 open or running | phase 3since Jun 2, 2025 | Jan 8, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2024First study: phase 1 study in Glabellar LinesFirst studyNCT06212960 · 20 enrolled · Korea, Republic of
- Jun 2, 2025Phase 3 study in Glabellar LinesNCT07013279 · 324 planned · Korea, Republic of
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07013279Glabellar Lines · Korea, Republic of | 3 | Not yet recruiting | Dec 31, 2025 | 324 |
| NCT06212960Glabellar Lines · Korea, Republic of | 1 | Completed | Feb 26, 2024 | 20 |
How it is read
Names in the registry
- “DWP712 inj.”, 1 entry
- “DWP712”, 1 entry
Codes read as this program: DWP712.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.